Gamma Secretase

• Gamma Secretase is a multi-subunit enzyme complex that cleaves proteins within the cell membrane.
• It plays a vital role in the Notch signaling pathway, which is critical for cell development and differentiation.
• A key function involves the processing of amyloid precursor protein (APP), leading to the generation of amyloid-beta peptides.
• Dysfunctional Gamma Secretase activity and the subsequent accumulation of amyloid-beta are central to the pathology of Alzheimer’s disease.
• Research into Gamma Secretase inhibitors and modulators represents a significant area for potential therapeutic interventions in neurodegenerative disorders.

What is Gamma Secretase?

Gamma Secretase refers to a complex of four integral membrane proteins that functions as an aspartyl protease, uniquely capable of cleaving its substrates within the hydrophobic environment of the cell membrane. This enzyme complex is highly conserved across species and is found in the endoplasmic reticulum, Golgi apparatus, and plasma membrane of cells. Its primary role involves the final proteolytic step in the processing of numerous transmembrane proteins, releasing their intracellular domains to participate in various signaling pathways.

The core components of the Gamma Secretase complex include presenilin (PSEN1 or PSEN2), nicastrin (NCT), anterior pharynx-defective 1 (APH-1), and presenilin enhancer 2 (PEN-2). Presenilin contains the catalytic aspartate residues necessary for proteolytic activity, while the other subunits are crucial for the assembly, stability, and substrate recognition of the complex. This intricate assembly ensures the precise and regulated cleavage of its diverse substrates.

Function and Mechanism of Gamma Secretase

The gamma secretase function and role extend beyond a single pathway, making it a critical player in cellular biology. One of its most well-known functions is its involvement in the Notch signaling pathway. Notch receptors are transmembrane proteins that, upon ligand binding, undergo sequential proteolytic cleavages, with Gamma Secretase performing the final cut. This releases the Notch intracellular domain (NICD), which then translocates to the nucleus to regulate gene transcription, influencing cell fate decisions, differentiation, and development.

The gamma secretase mechanism of action involves an initial cleavage by another protease (alpha-secretase or beta-secretase), which generates a membrane-tethered stub. Gamma Secretase then cleaves this stub within the transmembrane domain, releasing an intracellular fragment and an extracellular fragment. This unique intramembrane proteolysis is crucial for the regulated release of signaling molecules. Beyond Notch, Gamma Secretase processes over 100 known substrates, including:

• Amyloid Precursor Protein (APP)
• CD44 (a cell surface glycoprotein)
• ErbB-4 (a receptor tyrosine kinase)
• N-cadherin (a cell adhesion molecule)

The precise cleavage site within the transmembrane domain can vary depending on the substrate and cellular context, highlighting the complex regulatory mechanisms governing Gamma Secretase activity.

Gamma Secretase in Alzheimer’s Disease

The role of gamma secretase in Alzheimer’s disease (AD) is a central focus of neurodegenerative research. AD is characterized by the accumulation of amyloid plaques, which are primarily composed of amyloid-beta (Aβ) peptides. These Aβ peptides are generated from the sequential proteolytic cleavage of the amyloid precursor protein (APP).

First, APP is cleaved by beta-secretase (BACE1), producing a soluble APP fragment and a membrane-bound C-terminal fragment (CTFβ). Subsequently, Gamma Secretase cleaves this CTFβ within its transmembrane domain, releasing Aβ peptides of varying lengths, predominantly Aβ40 and Aβ42. The Aβ42 isoform is particularly prone to aggregation and is considered the primary initiator of amyloid plaque formation, a hallmark pathological feature of Alzheimer’s disease.

Mutations in the presenilin genes (PSEN1 and PSEN2), which encode the catalytic subunit of Gamma Secretase, are the most common cause of early-onset familial Alzheimer’s disease. These mutations often alter Gamma Secretase activity, leading to an increased production of the more aggregation-prone Aβ42 peptide. Consequently, Gamma Secretase has been a significant therapeutic target for AD, with efforts focused on developing Gamma Secretase inhibitors (GSIs) to reduce Aβ production or Gamma Secretase modulators (GSMs) to shift the cleavage preference towards less amyloidogenic Aβ isoforms.